摘要
目的探讨细胞质胸苷激酶(TK1)在肺癌临床诊断中的价值。方法选取2016年1~6月收住本院的肺癌患者50例,其中腺癌23例、鳞癌27例,门诊良性肺疾病患者50例以门诊健康体检者50例作为对照组,分别检测血清中TK1、Cy211、NSE、CEA水平及肺癌患者治疗前后血清相关标志物的水平。结果肺癌患者血清TK1、Cy211、NSE、CEA检测水平明显高于良性肺部疾病组和对照组,其敏感度分别为66%、58%、30%、23%,特异度分别为82%、86%、93%、89%。但是不同病理分型的肺癌患者血清相关标志物的表达无差异。肺癌患者治疗前血清肿瘤相关标志物的水平明显高于治疗后。结论 TK1对肺癌诊断的敏感度较Cy211、NSE、CEA高,可作为一种新的肿瘤标志物应用在肺癌早期筛查及疗效检测。
Objective To explore the clinical value of cytoplasm thymidine kinase 1 （TK1） in diagnosis of lung cancer. Methods Fifty in-patients with lung cancer were collected from Jan 2016 to Jun 2016, including 23 cases of adenocarcinoma, 27 cases of squamous cell carcinoma, 50 cases of benign lung disorders, and 50 cases of healthy individuals as control. Serum TK 1, Cy211, NSE, CEA, and other lung tumor markers as well, were examined. Results The levels of TK 1, Cy211, NSE, and CEA were remarkably higher in the lung cancer patients than in those of benign lung disorders, with the sensitivity rates of 66%, 58%, 30% and 23%, and specificity rates of 82%, 86%, 93% and 89%. No difference was noted among the cancer patients who presented different pathological types. The cancer patients showed a high level of tumor markers associated with lung cancer of pre- and post-treatments. Conclusion TK1 is sensitive an promising for screening and early diagnosis of lung cancer when compared with the other markers such as Cy 211, NSE, and CEA.
出处
《临床输血与检验》
CAS
2017年第2期167-169,共3页
Journal of Clinical Transfusion and Laboratory Medicine
关键词
细胞质胸苷激酶
肺癌
肿瘤标志物
Cytoplasm thymidine kinase （ TK 1 ） Lung cancer Tumor marker
